Literature DB >> 23125419

Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis.

Andrew M Tager.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23125419      PMCID： PMC3547105          DOI： 10.1165/rcmb.2012-0235ED

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN： 1044-1549            Impact factor:   6.914


× No keyword cloud information.
  17 in total

1.  A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

Authors:  J S Swaney; C Chapman; L D Correa; K J Stebbins; R A Bundey; P C Prodanovich; P Fagan; C S Baccei; A M Santini; J H Hutchinson; T J Seiders; T A Parr; P Prasit; J F Evans; D S Lorrain
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.

Authors:  Masayuki Tanaka; Shinichi Okudaira; Yasuhiro Kishi; Ryunosuke Ohkawa; Sachiko Iseki; Masato Ota; Sumihare Noji; Yutaka Yatomi; Junken Aoki; Hiroyuki Arai
Journal:  J Biol Chem       Date:  2006-07-06       Impact factor: 5.157

3.  Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.

Authors:  J S Swaney; C Chapman; L D Correa; K J Stebbins; A R Broadhead; G Bain; A M Santini; J Darlington; C D King; C S Baccei; C Lee; T A Parr; J R Roppe; T J Seiders; J Ziff; P Prasit; J H Hutchinson; J F Evans; D S Lorrain
Journal:  J Pharmacol Exp Ther       Date:  2010-12-15       Impact factor: 4.030

4.  Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.

Authors:  Flavia V Castelino; Jon Seiders; Gretchen Bain; Sarah F Brooks; Christopher D King; James S Swaney; Daniel S Lorrain; Jerold Chun; Andrew D Luster; Andrew M Tager
Journal:  Arthritis Rheum       Date:  2011-05

5.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.

Authors:  J S Munger; X Huang; H Kawakatsu; M J Griffiths; S L Dalton; J Wu; J F Pittet; N Kaminski; C Garat; M A Matthay; D B Rifkin; D Sheppard
Journal:  Cell       Date:  1999-02-05       Impact factor: 41.582

6.  Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q).

Authors:  Ming Yan Xu; Joanne Porte; Alan J Knox; Paul H Weinreb; Toby M Maher; Shelia M Violette; Robin J McAnulty; Dean Sheppard; Gisli Jenkins
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 7.  LPA receptors: subtypes and biological actions.

Authors:  Ji Woong Choi; Deron R Herr; Kyoko Noguchi; Yun C Yung; Chang-Wook Lee; Tetsuji Mutoh; Mu-En Lin; Siew T Teo; Kristine E Park; Alycia N Mosley; Jerold Chun
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

8.  LPA1 receptor activation promotes renal interstitial fibrosis.

Authors:  Jean-Philippe Pradère; Julie Klein; Sandra Grès; Charlotte Guigné; Eric Neau; Philippe Valet; Denis Calise; Jerold Chun; Jean-Loup Bascands; Jean-Sébastien Saulnier-Blache; Joost P Schanstra
Journal:  J Am Soc Nephrol       Date:  2007-11-14       Impact factor: 10.121

9.  The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.

Authors:  Andrew M Tager; Peter LaCamera; Barry S Shea; Gabriele S Campanella; Moisés Selman; Zhenwen Zhao; Vasiliy Polosukhin; John Wain; Banu A Karimi-Shah; Nancy D Kim; William K Hart; Annie Pardo; Timothy S Blackwell; Yan Xu; Jerold Chun; Andrew D Luster
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

10.  Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein.

Authors:  M L Stracke; H C Krutzsch; E J Unsworth; A Arestad; V Cioce; E Schiffmann; L A Liotta
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157
View more
  25 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 2.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

3.  Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice.

Authors:  Long Shuang Huang; Panfeng Fu; Priya Patel; Anantha Harijith; Tianjiao Sun; Yutong Zhao; Joe G N Garcia; Jerold Chun; Viswanathan Natarajan
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

4.  Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.

Authors:  Ya-Lan Dong; Xue-Yun Duan; Yu-Jin Liu; Heng Fan; Meng Xu; Qian-Yun Chen; Zhen Nan; Hui Wu; Shuang-Jiao Deng
Journal:  Inflammation       Date:  2019-10       Impact factor: 4.092

5.  A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of Bleomycin-Induced Pulmonary Fibrosis.

Authors:  Yogesh M Kulkarni; Sucharita Dutta; Anand Krishnan V Iyer; Clayton A Wright; Vani Ramesh; Vivek Kaushik; Oliver John Semmes; Neelam Azad
Journal:  Proteomics Clin Appl       Date:  2018-01-19       Impact factor: 3.494

6.  Role of the autotaxin-lysophosphatidic acid axis in glaucoma, aqueous humor drainage and fibrogenic activity.

Authors:  Leona T Y Ho; Anja Osterwald; Iris Ruf; Daniel Hunziker; Patrizio Mattei; Pratap Challa; Robin Vann; Christoph Ullmer; Ponugoti Vasanth Rao
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-10-21       Impact factor: 5.187

7.  Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis.

Authors:  Pengxiu Cao; Yoshiro Aoki; Linda Badri; Natalie M Walker; Casey M Manning; Amir Lagstein; Eric R Fearon; Vibha N Lama
Journal:  J Clin Invest       Date:  2017-02-27       Impact factor: 14.808

8.  Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.

Authors:  James I Fells; Sue Chin Lee; Yuko Fujiwara; Derek D Norman; Keng Gat Lim; Ryoko Tsukahara; Jianxiong Liu; Renukadevi Patil; Duane D Miller; R Jason Kirby; Sandra Nelson; William Seibel; Ruben Papoian; Abby L Parrill; Daniel L Baker; Robert Bittman; Gabor Tigyi
Journal:  Mol Pharmacol       Date:  2013-06-21       Impact factor: 4.436

9.  The autotaxin-LPA2 GPCR axis is modulated by γ-irradiation and facilitates DNA damage repair.

Authors:  Andrea Balogh; Yoshibumi Shimizu; Sue Chin Lee; Derek D Norman; Ruchika Gangwar; Mitul Bavaria; ChangSuk Moon; Pradeep Shukla; Radakrishna Rao; Ramesh Ray; Anjaparavanda P Naren; Souvik Banerjee; Souvik Banerje; Duane D Miller; Louisa Balazs; Louis Pelus; Gabor Tigyi
Journal:  Cell Signal       Date:  2015-05-28       Impact factor: 4.315

Review 10.  Bioactive lysophospholipids: role in regulation of aqueous humor outflow and intraocular pressure in the context of pathobiology and therapy of glaucoma.

Authors:  Ponugoti Vasantha Rao
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-27       Impact factor: 2.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.